NEW YORK and CAMBRIDGE, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Ajax Therapeutics, Inc., a biopharmaceutical company developing next generation JAK inhibitors for patients with myeloproliferative ...

– Data demonstrate superior efficacy compared to ruxolitinib, an approved type I JAK2 inhibitor, including reductions in mutant allele burden and bone marrow fibrosis, key markers of disease ...

Small group instruction remains one of the most powerful ways to accelerate math learning through differentiation. Yet in many classrooms, teachers feel pressured to create multiple versions of a ...

The Construction Justice Act would build pathways to the middle class for people like me. Good jobs rarely reached the families I grew up with in Far Rockaway. Too many of my friends and neighbors ...